ArticleScience advances2018
Article in Science advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Effect of IFN-Y +874 T/A polymorphism on clinical manifestations of dengue: a meta-analysis.Journal of genetics · 2021Pooled it
- Antigen-specific T cell responses following single and co-administration of tick-borne encephalitis, Japanese encephalitis, and yellow fever virus vaccines: Results from an open-label, non-randomized clinical trial-cohort.PLoS neglected tropical diseases · 2025Trial
- Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.PLoS neglected tropical diseases · 2023Trial
- Article
- Diagnostic Techniques for Dengue Virus.Current topics in microbiology and immunology · 2026Review
- Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program.Frontiers in immunology · 2026Review
- T Cell Responses During Dengue Infection.Current topics in microbiology and immunology · 2026Review
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- CD4Vaccines · 2025Article
- Pre-existing YFV-17D immunity mediates T cell cross-protection against dengue virus serotype 2 infection in mice.Communications biology · 2025Article
- Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025Review
- Future threats: Animal orthoflaviviruses that currently infect fewer than 100 people per year.Cell reports · 2025Review
- Seroprevalence and Placental Transfer of Zika and Dengue Virus Antibodies in Postpartum Women in Southeast Brazil.Journal of medical virology · 2025Article
- Orthoflavivirus circulation in South-East Queensland, Australia, before and during the 2021-2022 incursion of Japanese encephalitis virus assessed through sero-epidemiological survey of a sentinel equine population.One health (Amsterdam, Netherlands) · 2024Article
- Article
- Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus.Communications biology · 2024Article
- Novel approaches for the rapid development of rationally designed arbovirus vaccines.One health (Amsterdam, Netherlands) · 2023Article
- Increased Vaccination Diversity Leads to Higher and Less-Variable Neutralization of TBE Viruses of the European Subtype.Vaccines · 2023Article
- The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.Nature reviews. Immunology · 2023Review
- Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance.Antibodies (Basel, Switzerland) · 2023Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
How previous immunity influences immune memory recall and protection against related flaviviruses is largely unknown, yet encounter with multiple flaviviruses in a lifetime is increasingly likely. Using sequential challenges with dengue virus (DENV), yellow fever virus (YFV), and Japanese encephalitis virus (JEV), we induced cross-reactive cellular and humoral immunity among flaviviruses from differing serocomplexes. Antibodies against JEV enhanced DENV replication; however, JEV immunity was protective in vivo during secondary DENV1 infection, promoting rapid gains in antibody avidity. Mechanistically, JEV immunity activated dendritic cells and effector memory T cells, which developed a T follicular helper cell phenotype in draining lymph nodes upon secondary DENV1 infection. We identified cross-reactive epitopes that promote recall from a pool of flavivirus serocomplex cross-reactive memory CD4 T cells and confirmed that a similar serocomplex cross-reactive immunity occurs in humans. These results show that sequential immunizations for flaviviruses sharing CD4 epitopes should promote protection during a subsequent heterologous infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.